retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide ly3437943 triple agonist glp-1
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 15 - Nov 20


























:max_bytes(150000):strip_icc()/VWH-Nutrition-Collagen-178a8d63509143069f9e281239c6986d.jpg)